


# CONTENTS

## ETHNOPHARMACOLOGY



### **Ethnopharmacology - Volume 1**

**No. of Pages:** 290

**ISBN:** 978-1-905839-96-4 (eBook)

**ISBN:** 978-1-84826-996-5 (Print Volume)

### **Ethnopharmacology - Volume 2**

**No. of Pages:** 328

**ISBN:** 978-1-905839-97-1 (eBook)

**ISBN:** 978-1-84826-997-2 (Print Volume)

For more information of e-book and Print Volume(s) order, please [click here](#)

Or contact : [eolssunesco@gmail.com](mailto:eolssunesco@gmail.com)

## CONTENTS

## VOLUME I

<b>Ethnopharmacology: An Overview</b>	<b>1</b>
Elaine Elisabetsky, <i>Universidade Federal do Rio Grande do Sul, Brazil</i>	
Nina L. Etkin, <i>University of Hawai'i, USA</i>	

1. Introduction
  - 1.1. Defining Ethnopharmacology
2. Methods
3. Contexts of Medicinal Plant Use
  - 3.1. The Social Relations of Healing
  - 3.2. Criteria Used in the Selection of Plant Medicines
  - 3.3. Preparation of Plant Medicines
  - 3.4. Interactions among Plants and between Plants and Pharmaceuticals
  - 3.5. Outcome and Efficacy
    - 3.5.1. Do Medicines Work?
    - 3.5.2. How do Medicines Work?
    - 3.5.3. Efficacy versus effectiveness
4. Multicontextual Plant Use

<b>Historical Foundations of Botanical Medicine</b>	<b>13</b>
Daniel E. Moerman, <i>University of Michigan-Dearborn, USA</i>	

1. Introduction
2. Primates, Birds, and Butterflies
3. Shanidar
4. Ötzi
5. Herbals
6. Native American Medicinal Plants
  - 6.1. St. John's Wort, *Hypericum hypericoides* Crantz (Clusiaceae)
  - 6.2. Yarrow, *Achillea millefolium* L. (Asteraceae)
  - 6.3. Crane's-bill or Wild Geranium, *Geranium maculatum*.L. (Geraniaceae)
7. Conclusions

<b>Insights into Evolutionary Systems Via Chemobiological Data</b>	<b>25</b>
Otto Richard Gottlieb, <i>Universidade Federal Fluminense, Brazil</i>	
Maria Renata de M.B. Borin, <i>Universidade Federal Fluminense, Brazil</i>	

1. The Phytochemical Discovery of Brazil
2. Chemical Variability: Puzzles of the Lauraceae
  - 2.1. The Puzzle of Cinnamon (The Discovery of Amazonia)
  - 2.2. The Puzzle of Sassafras
3. A Plant is no Factory
4. How does Nature Work?
5. What is Quantitative Chemo-Biology?
6. What are Natural Products?
7. Chemobiological Language: What are its Grammatical Rules?
  - 7.1. Evolutionary Canalization
  - 7.2. Redox Potential
8. Medicinal Plants
  - 8.1. Traditional Knowledge
  - 8.2. Scientific Knowledge
  - 8.3. Shamanism x Science

9. Ethnobotany: Evolutionary Patterns for Useful Plants
  - 9.1. Regional Ethnobotanical Inventories
  - 9.2. Extensive Ethnobotanical Inventory
  - 9.3. Worldwide Ethnobotanical Inventories
10. Phytochemistry: Regulatory Mechanisms of Plant Bioactivity
11. Antagonism: A Unifying Concept?
12. Perspectives

### Contemporary Methodological Approaches in the Search for New Lead Compounds from Higher Plants

71

Emerson Ferreira Queiroz, *University of Geneva, Switzerland*Andrew Marston, *University of Geneva, Switzerland*Kurt Hostettmann, *University of Geneva, Switzerland*

1. Introduction
2. Approaches for the discovery of new drugs from higher plants
3. Selection of plant material
4. Biological and pharmacological targets
5. Chemical screening
  - 5.1. Metabolite profiling: a LC-multi-hyphenated strategy
  - 5.2. Problems encountered in metabolite profiling
  - 5.3. Application of LC/UV/MS and LC/NMR in phytochemical analysis
    - 5.3.1. Dereplication of flavanones and isoflavones in crude plant extracts
      - 5.3.1.1. Dereplication of the antifungal constituents of *Erythrina vogelii* by LC/UV/MS and on-flow LC/<sup>1</sup>H-NMR
        - 5.3.1.1.1. High resolution LC/UV/APCI-Q-TOF/MS/MS analyses
        - 5.3.1.1.2. Low-flow LC/<sup>1</sup>H-NMR with microfractionation
        - 5.3.1.1.3. LC/UV-DAD with post-column derivatisation
        - 5.3.1.1.4. *De novo* structure determination based on on-line data
      - 5.3.2. Stop-flow LC/<sup>1</sup>H-NMR with 2D correlation experiments for the structure elucidation of a flavanone of *Monotes englerii*
    - 5.4. Combination of LC/NMR and LC/MS with in-mixture NMR experiments for the investigation of labile constituents
      - 5.4.1. On-line characterisation of unstable cinnamic ester derivatives in *Jamesbrittenia fodina*
      - 5.4.2. Study of epimerisation reactions
    - 5.5. On-line absolute configuration determination
  6. Isolation of active principles and their structure determination
  7. Conclusion

### Integrating Ethnographic and Ecological Perspectives for Ethnopharmacology Field Research

99

Nina L. Etkin, *University of Hawai'i, USA*Tamara Ticktin, *University of Hawai'i, USA*

1. Introduction
2. Anthropological (Ethnographic) Field Methods
  - 2.1. Informed Consent and Research Ethics
  - 2.2. Identifying/Inviting Study Participants
  - 2.3. Key Respondents/Informants
  - 2.4. Participant Observation
  - 2.5. Semi- and Unstructured Interviews and Questionnaires
    - 2.5.1. Unstructured Interviews
    - 2.5.2. Semi-Structured Interviews
    - 2.5.3. Frame Elicitation
    - 2.5.4. Cultural Domain Analysis
    - 2.5.5. Free-Listing

- 2.5.6. Pile Sorts
- 2.5.7. Triad Exercise
- 2.5.8. Questionnaires
- 2.6. Discourse, Narrative, and Text Analysis
- 2.7. Group Interview Methods
  - 2.7.1. Community Interviews
  - 2.7.2. Natural Group
  - 2.7.3. Consensus Panel
  - 2.7.4. Focus Group
- 2.8. Quantitative Data
- 2.9. Prioritizing (Ethnographic) Methods
- 3. Integrating Ethnographic and Ecological Field Methods
  - 3.1. Ecocultural Research Questions in Ethnopharmacology
  - 3.2. Examining Ecological Factors that Influence the Collection of Medicinal Plants
  - 3.3. Distinguishing Environmental Versus Genetic Variation
  - 3.4. Assessing Relationships between Anthropogenic Landscape Changes and Medicinal Plants
  - 3.5. Ecocultural Research on Medicinal Plant Conservation
  - 3.6. Variation in Plant Collection and Management Methods
  - 3.7. Assessing the Ecological Impacts of Variation in Plant Collection
  - 3.8. Participatory Ecological Research Methods Applied to Medicinal Ethnobotany
  - 3.9. Assessing the Ecological Consequences of Medicinal Plant Harvest on Other Organisms
- 4. Conclusion

### **Managing Ethnopharmacological Data: Herbaria, Relational Databases, Literature** 118

John Richard Stepp, *University of Florida, USA*

Michael B. Thomas, *Univeristy of Hawai'i, USA*

- 1. Introduction
- 2. Historical Trends
- 3. Present Trends
  - 3.1. Ethnopharmacological Databases
  - 3.2. New Models for Ethnopharmacological Databases
  - 3.3. Managing Field Data and Workflow
  - 3.4. Voucher Specimens and Ethnopharmacological data
- 4. Conclusions and Future Challenges

### **Professional Ethics and Ethnopharmacology** 133

Kelly P. Bannister, *University of Victoria, Canada*

- 1. Introduction
- 2. What are Professional Ethics?
  - 2.1. Ethnopharmacology as a Profession
  - 2.2. Unearthing a Professional Ethic for Ethnopharmacology
- 3. External Standards for Ethnopharmacology
  - 3.1. Approvals
  - 3.2. Permissions and Permits
    - 3.2.1. Documentation of Cultural Knowledge
    - 3.2.2. Genetic Resources
  - 3.3. Compensation and Benefit-sharing
  - 3.4. Credit and Rights Issues
  - 3.5. Community Protocols
- 4. Remaining Challenges for Ethnopharmacology as a Profession
- 5. Conclusions

### **Medicinal Plants in the Evolution of Therapeutics—A Case of Applied Ethnopharmacology** 160

Fernando Ortega-Perez, *Universidad San Francisco de Quito, Ecuador*

1. Introduction
2. Medicinal plants in the evolution of biomedicine
  - 2.1. Medicinal plants as landmarks in medical history
    - 2.1.1. Ancient times
    - 2.1.2. Arabic and Greek legacies
    - 2.1.3. Last century of the second millennium legacy
  - 2.2. Medicinal plants as sources of prototypic agents
3. Disease Control in a cross-cultural context: A case of applied ethnopharmacology to common intestinal parasitism
  - 3.1. Knowledge accumulated by American peoples in the treatment of worms
  - 3.2. Ethnopharmacology applied to intestinal worms. A Cost-effectiveness study for community control of ascariasis comparing herbal and pharmaceutical treatments in Ecuador
4. Material and Methods
  - 4.1. Study design
  - 4.2. Study Subjects
  - 4.3. Effectiveness assessment
5. Results and analysis
  - 5.1. Population's living conditions
  - 5.2. Prevalence of parasitism
  - 5.3. Risk factors of Ascariasis: association between ascariasis and selected explanatory variables
  - 5.4. Regression Analysis
  - 5.5. Analysis of risk factors
  - 5.6. Treatment groups
  - 5.7. Evaluation of effectiveness of treatments
  - 5.8. Cost/effectiveness analysis
6. Discussion: Health, sustainable development and socio-economic aspects of treating the most common parasitic disease in the world
  - 6.1. Multidisciplinary approach
  - 6.2. Importance of ecological preservation and human security
  - 6.3. Limitations of this study
7. Recommendations for further research
8. Policy implications

### **Plants as a Source of Anti-Cancer Agents**

183

Gordon M. Cragg, *National Cancer Institute, USA*

David Newman, *National Cancer Institute, USA*

1. Introduction
2. Plant-Derived Anti-Cancer Agents in Clinical Use
3. Plant-Derived Anti-Cancer Agents in Clinical Development
4. Targeting Natural Products
5. Plant-Derived Anti-tumor Agents in Preclinical Development
6. Cell Cycle Target Inhibition and Anti-cancer Drug Discovery
7. Conclusions

### **Traditional Medicinal Plants for the Treatment and Prevention of Human Parasitic Diseases**

199

Merlin L. Willcox, *Research Initiative on Traditional Antimalarial Methods, Buckingham, UK*

Benjamin Gilbert, *FarManguinhos-FIOCRUZ, Brazil*

1. Introduction
2. Protozoa
  - 2.1. Blood protozoa
    - 2.1.1. Malaria
      - 2.1.1.1. Importance of traditional medicine in treatment of malaria
      - 2.1.1.2. Important plant species and their active ingredients
        - 2.1.1.2.1. Ethnobotanical studies

- 2.1.1.2.2. Pharmacological studies
- 2.1.1.2.3. Clinical safety and efficacy
- 2.1.1.3. Vector control
  - 2.1.1.3.1. Mosquito Repellents
  - 2.1.1.3.2. Larvicides
- 2.1.1.4. Future Directions for Research
- 2.1.2. Trypanosomiasis
  - 2.1.2.1. Human African Trypanosomiasis (sleeping sickness)
    - 2.1.2.1.1. The importance of traditional medicine for African trypanosomiasis
    - 2.1.2.1.2. Important plant species and their active ingredients
    - 2.1.2.1.3. Clinical safety and efficacy
  - 2.1.2.2. American Trypanosomiasis (Chagas' disease)
    - 2.1.2.2.1. Important plant species and their active ingredients
    - 2.1.2.2.2. Vector control
- 2.2. Tissue protozoa
  - 2.2.1. Leishmaniasis
    - 2.2.1.1. The importance of traditional medicine for cutaneous leishmaniasis
    - 2.2.1.2. The importance of traditional medicine for visceral leishmaniasis
    - 2.2.1.3. Important plant species and their active ingredients
    - 2.2.1.4. Clinical safety and efficacy
    - 2.2.1.5. Vector control
- 2.3. Intestinal protozoa
  - 2.3.1. Importance of Traditional Medicine
  - 2.3.2. Important plant species and active ingredients
- 3. Helminths
  - 3.1. Nematodes (roundworms)
    - 3.1.1. Intestinal nematodes
      - 3.1.1.1. Importance of traditional medicine
      - 3.1.1.2. Important plant species and active ingredients
      - 3.1.1.3. Clinical safety and efficacy
    - 3.1.2. Blood nematodes
  - 3.2. Cestodes (tapeworms)
  - 3.3. Trematodes (flat worms)
    - 3.3.1. Schistosomiasis
      - 3.3.1.1. Importance of traditional medicine
      - 3.3.1.2. Important plant species and active ingredients
      - 3.3.1.3. Clinical safety and efficacy
    - 3.3.2. Flukes
    - 3.3.3. Control of intermediate hosts
- 4. Conclusions

**Index** 227

**About EOLSS** 233

## VOLUME II

**Plants and Plant Substances Against AIDS and Other Viral Diseases** 1

Paul Cos, *University of Antwerp, Belgium*

Louis L. Maes, *University of Antwerp, Belgium*

Dirk Vanden Berghe, *University of Antwerp, Belgium*

Nina Hermans, *University of Antwerp, Belgium*

Sandra S. Apers, *University of Antwerp, Belgium*

Arnold J Vlietinck, *University of Antwerp, Belgium*

1. Introduction
2. The plant kingdom as source of new antiviral agents
  - 2.1. Opportunities and challenges
  - 2.2. Selection of plants
  - 2.3. Preparation of plant extracts
3. Antiviral test methodology
4. Plant-derived anti-human immunodeficiency virus (anti-HIV) agents
  - 4.1. AIDS and anti-HIV drugs
  - 4.2. AIDS and traditional medicine
  - 4.3. Plant-derived anti-HIV agents
    - 4.3.1. Alkaloids
    - 4.3.2. Carbohydrates
    - 4.3.3. Coumarins
    - 4.3.4. Flavonoids
    - 4.3.5. Lignans
    - 4.3.6. Naphthodiantrones
    - 4.3.7. Phenolics
    - 4.3.8. Phorbol esters
    - 4.3.9. Proteins
    - 4.3.10. Tannins
    - 4.3.11. Terpenes
5. Plant-derived anti-herpes simplex virus (anti-HSV) and anti-cytomegalovirus (anti-CMV) agents
  - 5.1. The human herpes virus (HHV) family and anti-HHV drugs
  - 5.2. Plant-derived anti-HSV and anti-CMV agents
    - 5.2.1. Alkaloids
    - 5.2.2. Carbohydrates
    - 5.2.3. Flavonoids
    - 5.2.4. Lignans
    - 5.2.5. Phenolics
    - 5.2.6. Proteins
    - 5.2.7. Tannins
    - 5.2.8. Terpenes
    - 5.2.9. n-Docosanol
6. Plant-derived anti-influenza virus agents
  - 6.1. Influenza and anti-influenza drugs
  - 6.2. Plant-derived anti-influenza virus agents
7. Conclusions

### Botanical Analgesic and Anti-Inflammatory Drugs

36

Joao B. Calixto, *Universidade Federal de Santa Catarina (UFSC), Brazil*  
 Maria Martha Campos, *Universidade Federal de Santa Catarina (UFSC), Brazil*  
 Adair R.S. Santos, *Universidade Federal de Santa Catarina (UFSC), Brazil*

1. Introduction
2. Principal plants that have contributed to the development of modern analgesic and anti-inflammatory drugs
  - 2.1. *Papaver somniferum*
  - 2.2. *Salix* species
  - 2.3. *Cannabis sativa*
  - 2.4. *Capsicum* sp.
  - 2.5. *Panax ginseng*
  - 2.6. *Tanacetum parthenium*
  - 2.7. *Aconitum* sp.
3. New plant-derived substances with potential antinociceptive or anti-inflammatory properties
  - 3.1. *Siphocampylus verticillatus*
  - 3.2. *Drymis winteri*
  - 3.3. *Hedyosmum brasiliense*

- 3.4. *Phyllanthus* sp.
- 3.5. *Protium* sp.
4. Possible biological targets for botanical-derived substances with potential anti-inflammatory and antinociceptive properties
5. Conclusion

### The Search for Plants to Manage Diabetes

61

Steven R. King, *Napo Pharmaceuticals Inc., USA*Charles Limbach, *Big Sur Health Center, USA*

1. Introduction
  - 1.1. Diabetes Type 1
  - 1.2. Diabetes Type 2
2. Need for Medicinal Plant Discovery for Type 2 Diabetes
3. Methods for Searching for Type 2 Diabetes Active Plants
  - 3.1. Ethnomedical search for plants to treat Type 2 diabetes
  - 3.2. Field research methods for identifying plant to manage type 2 diabetes
  - 3.3. Field studies on efficacy of plants utilized to treat type 2 diabetes
  - 3.4. In vivo animal models for screening, testing and developing plants, extracts and compounds to treat type 2 diabetes
  - 3.5. Masoprocol: an example of an investigational drug candidate for type 2 diabetes derived from traditional knowledge
    - 3.5.1. Pre clinical studies
    - 3.5.2. Safety studies
4. Selected examples of medicinal plants under investigation for antidiabetic activity
  - 4.1. *Momordica charantia*
  - 4.2. *Trigonella foenum-graecum*
  - 4.3. *Opuntia ficus-indica*
  - 4.4. *Phyllanthus niruri*
5. Compounds often associated with hypoglycemic activity in medicinal plant research
6. Conclusion

### Medicinal Plants for the Prevention and Treatment of Coronary Heart Disease

75

Gail B. Mahady, *University of Illinois at Chicago, USA*

1. Introduction
  - 1.1. Coronary Heart Disease and treatment
2. Artichoke (*Cynara scolymus*)
  - 2.1. Clinical studies
  - 2.2. *In vitro* and *in vivo* studies
3. Garlic (*Allium sativum*)
  - 3.1. Clinical studies
    - 3.1.1. Antihypercholesterolemic activity
    - 3.1.2. Antihypertensive activity
    - 3.1.3. Effects on platelet aggregation and myocardial infarction
4. Guggul (*Commiphora mukul*)
  - 4.1. Clinical studies
    - 4.1.1. Antihyperlipidemic effects
5. Ginkgo (*Ginkgo biloba*)
  - 5.1. Clinical studies
    - 5.1.1. Antioxidant activity
    - 5.1.2. Inhibition of Platelet Aggregation
    - 5.1.3. Hematological effects
  - 5.2. In vitro and in vivo studies
    - 5.2.1. Antioxidant and antiplatelet activities
    - 5.2.2. Enhancement in coronary blood flow



- 5.2.3. Vasodilatation
- 5.2.4. Inhibition of Platelet Aggregation and Thrombus Formation
- 5.2.5. Blood Pressure Regulation
- 6. Hawthorn (*Crataegus* species)
  - 6.1. Clinical studies
    - 6.1.1. Cardiac insufficiency
  - 6.2. In vitro and in vivo studies
    - 6.2.1. Inotropic effects
    - 6.2.2. Antiarrhythmic effects
    - 6.2.3. Ischemic-reperfusion injury
    - 6.2.4. Vasodilation and coronary blood flow
    - 6.2.5. Antihypertensive effects
    - 6.2.6. Antioxidant effects
- 7. Red wine (*Vitis vinifera*) and resveratrol
  - 7.1. In vitro studies
    - 7.1.1. Effects on nitric oxide
    - 7.1.2. Effects on infectious components
- 8. Saffron (*Crocus sativus*)
  - 8.1. Clinical studies
    - 8.1.1. Antioxidant effects
  - 8.2. In vitro and in vivo studies
    - 8.2.1. Antiatherosclerotic effects
    - 8.2.2. Antihypertensive activity
- 9. Tea (*Camellia sinensis*)
  - 9.1. Clinical studies
- 10. Conclusion

### The Search for Plants to Manage Neurodegenerative Diseases

100

Peter John Houghton, *King's College London, UK*Melanie-Jayne Rosemarie Howes, *Jodrell Laboratory, UK*

- 1. Introduction
  - 1.1. Neurodegenerative disease in perspective
  - 1.2. Searching for symptoms in traditional medicine
  - 1.3. Approaches to scientific investigation
  - 1.4. Plants as a source of useful therapeutic agents in neurodegenerative diseases
- 2. Plants and their constituents from Ayurvedic medicine
  - 2.1. *Withania somnifera*
  - 2.2. *Bacopa monniera*
  - 2.3. *Centella asiatica*
  - 2.4. *Mucuna pruriens*
- 3. Plants and their constituents from Chinese traditional medicine (TCM)
  - 3.1. *Huperzia serrata*
  - 3.2. *Ginkgo biloba*
  - 3.3. *Salvia miltiorrhiza*
  - 3.4. Soya
- 4. Plants and their constituents from European herbal medicine
  - 4.1. Galantamine
  - 4.2. *Salvia* spp.
  - 4.3. Ergot and its alkaloids
- 5. Plants and their constituents from African and South American traditional medicine
  - 5.1. *Physostigma venenosum*
  - 5.2. *Ptychopetalum olacoides*
  - 5.3. *Banisteriopsis caapi*
- 6. Conclusions

**Psychoactive Botanicals in Ritual, Relegion, and Shamanism**

128

Glenn H. Shepard Jr., *National Institute of Amazonian Research (INPA), Brazil*

1. Introduction
  - 1.1. Definitions and Scope
  - 1.2. Cross-Disciplinary Perspectives
2. Shamanism, Psychoactive Plants, and the Origins of Religion
  - 2.1. Trance and Altered States of Consciousness
  - 2.2. Evidence from Ancient Art
3. Psychoactive Botanicals: A World Overview
  - 3.1. Africa
    - 3.1.1. *Coffea arabica*: The Wine of Islam
    - 3.1.2. *Tabernanthe iboga*: Way to the Ancestors
  - 3.2. Europe and Asia
    - 3.2.1. *Amanita muscaria*: Divine Mushroom of Immortality?
    - 3.2.2. *Claviceps paspali*: Key to the Eleusinian Mysteries?
    - 3.2.3. *Atropa belladonna*, *Datura metel*, *Hyoscyamus niger*: Nightshades for Oracles, Witches, and Beautiful Ladies
    - 3.2.4. *Cannabis sativa*: Hemp for Fiber, Medicine, and Delight
  - 3.3. Oceania
    - 3.3.1. *Piper methysticum*: Kava-kava
    - 3.3.2. *Boletus manicus*: Kuma Mushroom Madness
  - 3.4. The Americas
    - 3.4.1. *Nicotiana tabacum*: Magical Breath of Shamans
    - 3.4.2. *Datura*, *Brugmansia*, *Brunfelsia*: Nightshades for Visions, Healing, and Divination
    - 3.4.3. *Psilocybe mexicana*: Flesh of the Gods
    - 3.4.4. *Lophophora williamsii*, *Trichocereus pachanoi*: hallucinogenic cacti of Mexico and Peru
    - 3.4.5. *Virola theiodora*, *Anadenanthera peregrina*: hallucinogenic snuffs of the Northwest Amazon
    - 3.4.6. *Banisteriopsis caapi*: Vine of the Soul
    - 3.4.7. *Cyperus*: Ergot-Infested Sedges
    - 3.4.8. *Erythroxylum coca*: From Sun King to Drug Lord
4. Contemporary Issues
5. Conclusion

**Primates, Plants, and Parasites: The Evolution of Animal Self-Medication and Ethnomedicine**

183

Michael A. Huffman, *Section of Ecology, Primate Research Institute, Kyoto University, JAPAN*Sylvia K. Vitazkova, *EPSCoR, University of Virgin Islands, 2 Brewer's Bay, St. Thomas, USVI, USA.*

1. Introduction
2. Animal self-medication and ethnomedicine
3. The impact of parasites on the evolution of self-meditative behavior
4. Food as medicine in animals and humans
5. Use of plants as medicine by chimpanzees in the wild
  - 5.1. Whole leaf swallowing and the physical expulsion of parasite
  - 5.2. *Vernonia amygdalina* and bitter pith chewing behavior
  - 5.3. The ethnomedicine and phytochemistry of bitter pith chewing
6. A link between animal self-medication and ethnomedicine
7. Tongwe ethnozoology and health care
8. Future studies and directions of research

**Ethnopharmacology and Health Care in the Developing World**

202

Ruth Kutalek, *Medical University of Vienna, Austria*Armin Prinz, *Medical University of Vienna, Austria*

1. Introduction

2. Indigenous Plants in Western Medicine
  - 2.1. Plants from Indigenous African Medical Systems
  - 2.2. Plants from other Medical Traditions
  - 2.3. The Case of *Artemisia annua* L.
3. Biodiversity and Sustainability
  - 3.1. *Taxus brevifolia* and Biodiversity
  - 3.2. The Case of *Rauwolfia* spp.
  - 3.3. *Prunus africana*
  - 3.4. Indigenous Strategies
4. Safety and Efficacy of Medicines
5. Pharmaceutical Anthropology
  - 5.1. Indigenous Interpretations of Medicines
  - 5.2. Injections: Skepticism towards Biomedicine
  - 5.3. Accessibility and Distribution of Medicines
6. Conclusion

**Safety of Traditional Remedies**

223

Michael Heinrich, *University of London, UK*

1. Introduction—safety of phytotherapeutic preparations
2. Examples of safety issue with traditional remedies
  - 2.1. Acute toxicity
  - 2.2. Chronic Toxicity
  - 2.3. Drug interactions
  - 2.4. Adulterations
  - 2.5. Quality of botanical products used
3. How frequent are toxic effects of traditional remedies
4. Quality control measures
5. Toxicity of traditional medicines—a public health perspective
6. Conclusion

**Medicinal Plants in International Trade: Conservation and Equity Issues**

241

Sarah Laird, *University College London, UK*

1. Introduction
2. Conservation and Sustainable Use of Medicinal Plants
3. Equity Issues in the Medicinal Plant Trade
4. The Botanical Medicine Industry
  - 4.1. Overview of the Market
  - 4.2. The Use of Traditional Knowledge in Product Development, Formulation and Marketing
  - 4.3. Raw Material Sourcing
  - 4.4. Certification of Raw Materials
5. The Pharmaceutical Industry
  - 5.1. Overview of Markets and the Role of Natural Products
  - 5.2. The Use of Traditional Knowledge in R&D
  - 5.3. Raw Material Sourcing
6. Conclusion

**The Future of Ethnopharmacology: Seeking a Transdisciplinary and Culturally Germane Science**

258

Nina L. Etkin, *University of Hawai'i, USA*Elaine Elisabetsky, *Universidade Federal do Rio Grande do Sul, Brazil*

1. Introduction: Defining Ethnopharmacology
  - 1.1. The International Society for Ethnopharmacology and the Journal of Ethnopharmacology

2. Objectives of Ethnopharmacology Research
  - 2.1. Critical Reviews and Challenges for an Integrated Ethnopharmacology
3. Future Trends

**Index** **266**

**About EOLSS** **271**